Pfizer has signed a licensing agreement worth up to $2.63 billion with Starna Therapeutics to develop next-generation in vivo CAR-T treatments. The deal gives Pfizer exclusive rights outside Greater China to three preclinical programs targeting autoimmune diseases. 🔹 Key Highlights Total Deal Value: Up to $2.63 billion. Upfront Payment: $330 million. Milestone Payments: Up to $2.3 billion in development and commercial milestones, plus royalties. Pipeline Access: Exclusive rights outside Greater China to three preclinical in vivo CAR-T programs. Target Areas: Programs are focused on autoimmune diseases. Technology Access: The agreement includes access to Starna's RNA-based CAR-T technology for immunology and oncology. Expansion Options: Pfizer has options to expand licensing rights into Greater China. 💡 Why It Matters The agreement expands Pfizer's interest in next-generation cell therapies beyond traditional oncology applications into autoimmune diseases. In vivo CAR-T technology aims to generate CAR-T cells directly inside the body, potentially changing how these treatments are developed and delivered. However, the programs remain preclinical, making clinical validation and development timelines key risks. 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified